ReviewAttention deficit and hyperactivity disorders2010
Toward a better understanding of ADHD: LPHN3 gene variants and the susceptibility to develop ADHD.
Review in Attention deficit and hyperactivity disorders, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- The expanding roles of adhesion GPCRs in neural circuit assembly.Molecules and cells · 2026Review
- Unraveling Attention-Deficit/Hyperactivity Disorder Etiology: Current Challenges and Future Directions in Treatment.NeuroSci · 2025Review
- Phasic dopamine release in two different rat models of attention-deficit/hyperactivity disorder: Spontaneously hypertensive rats (SHR) versus Lphn3 knockout rats.Neuroscience · 2025Article
- adgrl3.1-deficient zebrafish show noradrenaline-mediated externalizing behaviors, and altered expression of externalizing disorder-candidate genes, suggesting functional targets for treatment.Translational psychiatry · 2023Article
- Impulsive choice in two different rat models of ADHD-Spontaneously hypertensive andFrontiers in neuroscience · 2023Article
- ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the incretin polypeptide GIP.Scientific reports · 2022Article
- Latrophilin-3 heterozygous versus homozygous mutations in Sprague Dawley rats: Effects on egocentric and allocentric memory and locomotor activity.Genes, brain, and behavior · 2022Article
- An assessment of executive function in two different rat models of attention-deficit hyperactivity disorder: Spontaneously hypertensive versus Lphn3 knockout rats.Genes, brain, and behavior · 2021Article
- A novel role for the ADHD risk gene latrophilin-3 in learning and memory in Lphn3 knockout rats.Neurobiology of disease · 2021Article
- Impulsive and Omission Errors: Potential Temporal Processing Endophenotypes in ADHD.Brain sciences · 2021Article
- Latrophilin-3 disruption: Effects on brain and behavior.Neuroscience and biobehavioral reviews · 2021Review
- Knockout of latrophilin-3 in Sprague-Dawley rats causes hyperactivity, hyper-reactivity, under-response to amphetamine, and disrupted dopamine markers.Neurobiology of disease · 2019Article
- The role of pre-, peri-, and postnatal risk factors in bipolar disorder and adult ADHD.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- Article
- Genetics of attention deficit hyperactivity disorder.Molecular psychiatry · 2019Review
- ADGRL3 (LPHN3) variants predict substance use disorder.Translational psychiatry · 2019Article
- ADGRL3 (LPHN3) variants are associated with a refined phenotype of ADHD in the MTA study.Molecular genetics & genomic medicine · 2016Article
- Behavioral and transcriptomic profiling of mice null for Lphn3, a gene implicated in ADHD and addiction.Molecular genetics & genomic medicine · 2016Article
- Attention deficit hyperactivity disorder: genetic association study in a cohort of Spanish children.Behavioral and brain functions : BBF · 2016Article
- A common genetic network underlies substance use disorders and disruptive or externalizing disorders.Human genetics · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
During the past 15 years, an impressive amount of genetic information has become available in the research field of psychiatry, particularly as it relates to attention-deficit/hyperactivity disorder (ADHD). However, the classical clinical approach to ADHD has minimally affected and not significantly been improved by this genetic revolution. It is difficult to predict how long it will take for genetic findings to alter the way clinicians treat patients with ADHD. New medications or treatment protocols may take years to become routine clinical practice. However, when taken together, recent successes in genomics, pharmacogenomics, and genetic epidemiology have the potential (1) to prevent comorbid consequences of ADHD, (2) to individualize therapies for patients with ADHD, and (3) to define new epidemiological policies to aid with the impact of ADHD on society. Here, we present an overview of how genetic research may affect and improve the quality of life of patients with ADHD: as an example, we use the discovery of LPHN3, a new gene in which variants have recently been shown to be associated with ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.